Invention Application
- Patent Title: Use of Ureidomustine (BO-1055) in Cancer Treatment
-
Application No.: US15745639Application Date: 2016-08-17
-
Publication No.: US20190008808A1Publication Date: 2019-01-10
- Inventor: Malcolm Moore , Jae-Hung Shieh , Tsann-Long Su , Te-Chang Lee
- Applicant: Academia Sinica , Memorial Sloan Kettering Cancer Center
- International Application: PCT/US16/47264 WO 20160817
- Main IPC: A61K31/167
- IPC: A61K31/167 ; A61P35/02
Abstract:
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
Public/Granted literature
- US10548861B2 Use of ureidomustine (BO-1055) in cancer treatment Public/Granted day:2020-02-04
Information query
